BioWorld

Oct. 3, 2002

Elan's Abelcet, Sales Force Go To Enzon For $370M

Enzon Inc. signed an agreement with troubled Irish pharmaceutical company Elan Corp. plc to buy the North American and Japanese rights to Abelcet, Elan's drug for severe fungal infections, for $370 million in cash. (BioWorld Today) Read More

Biosynexus Enters Antibacterial Deal With GSK Unit For $120M

Incurable Prion Diseases Open Crack To Resistance, Diagnosis, Drug Treatment, Gene Therapy

Panel's Advice Is Take The Money, Don't Count On An Open Window

Adherex, Oxiquant To Merge; Four Cancer Drugs In Basket

Deltagen Realignment Reduces Staff 30 Percent, Shuts Facility

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...